|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1997-4-28
|
|
pubmed:abstractText |
To measure the extent of HIV resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC, lamivudine) within the context of monotherapy and to assess the presence of the M184V substitution in the case of 3TC-resistant viruses. Whether the success of 3TC in clinical trials could be due, in part, to an increase in the fidelity of HIV reverse transcriptase conferred by the M184V substitution was also considered.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10 Suppl 5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
S3-10
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9030390-Adult,
pubmed-meshheading:9030390-Anti-HIV Agents,
pubmed-meshheading:9030390-Child,
pubmed-meshheading:9030390-Child, Preschool,
pubmed-meshheading:9030390-Drug Resistance, Microbial,
pubmed-meshheading:9030390-Female,
pubmed-meshheading:9030390-HIV Antibodies,
pubmed-meshheading:9030390-HIV Infections,
pubmed-meshheading:9030390-HIV Reverse Transcriptase,
pubmed-meshheading:9030390-HIV-1,
pubmed-meshheading:9030390-Humans,
pubmed-meshheading:9030390-Lamivudine,
pubmed-meshheading:9030390-Male,
pubmed-meshheading:9030390-Mutation,
pubmed-meshheading:9030390-Neutralization Tests,
pubmed-meshheading:9030390-Viral Load
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
|
|
pubmed:affiliation |
McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
